enGene Therapeutics (ENGNW) SEC Filings, Jul 8-10, 2025

enGene Holdings Inc. (NASDAQ:ENGN, ENGNW) filed an 8-K covering board and management changes effective July 7-8, 2025.

• Director resignation: Jasper Bos resigned from the Board on July 7, 2025; the company states there was no disagreement regarding operations, policies or practices.
• Board appointments: The Board appointed Philip Astley-Sparke to fill the vacancy as of July 8, 2025, for the remainder of Bos’s term expiring at the 2026 AGM. The Board then increased its size from seven to nine and named William Grossman and Michael Heffernan as additional directors, each serving until the next AGM.
• Compensation & indemnification: All three new directors will participate in the company’s standard independent-director compensation plan and enter into indemnification agreements identical to those filed as Exhibits 10.17 and 10.18 to the 2024 Annual Report.
• Committee assignments: Not yet determined for the new directors.
• Management promotions (Reg FD disclosure): A July 8 press release (Exhibit 99.1) announced promotions of Matthew Boyd to Chief Regulatory Officer and Jill Buck to Chief Development Officer.

No transactions requiring disclosure under Item 404(a) were reported. The information furnished under Item 7.01 is expressly not deemed “filed” under the Exchange Act.